Abstract:The repertoire of currently available antiviral drugs spans therapeutic applications against a number of important human pathogens distributed worldwide. These include cases of the pandemic severe acute respiratory coronavirus type 2 (SARS-CoV-2 or COVID-19), human immunodeficiency virus type 1 (HIV-1 or AIDS), and the pregnancy- and posttransplant-relevant human cytomegalovirus (HCMV). In almost all cases, approved therapies are based on direct-acting antivirals (DAAs), but their benefit, particularly in long-term applications, is often limited by the induction of viral drug resistance or side effects. These issues might be addressed by the additional use of host-directed antivirals (HDAs). As a strong input from long-term experiences with cancer therapies, host protein kinases may serve as HDA targets of mechanistically new antiviral drugs. The study demonstrates such a novel antiviral strategy by targeting the major virus-supportive host kinase CDK7. Importantly, this strategy focuses on highly selective, 3D structure-derived CDK7 inhibitors carrying a warhead moiety that mediates covalent target binding. In summary, the main experimental findings of this study are as follows: (1) the in vitro verification of CDK7 inhibition and selectivity that confirms the warhead covalent-binding principle (by CDK-specific kinase assays), (2) the highly pronounced antiviral efficacies of the hit compounds (in cultured cell-based infection models) with half-maximal effective concentrations that reach down to picomolar levels, (3) a particularly strong potency of compounds against strains and reporter-expressing recombinants of HCMV (using infection assays in primary human fibroblasts), (4) additional activity against further herpesviruses such as animal CMVs and VZV, (5) unique mechanistic properties that include an immediate block of HCMV replication directed early (determined by Western blot detection of viral marker proteins), (6) a substantial drug synergism in combination with MBV (measured by a Loewe additivity fixed-dose assay), and (7) a strong sensitivity of clinically relevant HCMV mutants carrying MBV or ganciclovir resistance markers. Combined, the data highlight the huge developmental potential of this host-directed antiviral targeting concept utilizing covalently binding CDK7 inhibitors.

Medicinal chemistry strategies toward host targeting antiviral agents

Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses

A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses

Medicinal Chemistry Strategies For Discovering Antivirals Effective Against Drug-Resistant Viruses

Current Progress in Antiviral Strategies.

Systematic Optimization of Host-Directed Therapeutic Targets and Preclinical Validation of Repositioned Antiviral Drugs

Recent advancement in small molecules as HCV inhibitors.

Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets

Anti-virus reagents targeting the capsid protein assembly

Recent Advances in the Molecular Design and Applications of Viral RNA-targeting Antiviral Modalities

Repurposing host-based therapeutics to control coronavirus and influenza virus

A comprehensive review on targeting cluster of differentiation: An attractive strategy for inhibiting viruses through host proteins

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges

Progress on AIDS drug targets and small molecule inhibitors

An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity

Novel strategies in rational design of anti-HIV agents:multitarget and multivalency ligands

Clathrin-mediated endocytosis and broad-spectrum antivirals

Medicinal Chemistry Insights into Antiviral Peptidomimetics

Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics

Recent Progress and Future Prospects of Direct-Acting Antiviral Agents for Chronic Hepatitis C